Genmab — August 2020
-
Lidt cd20/cd3 weekendlæsning https://www.nature.com/articles/s41540-02
0-00145-7 -
-
God morgen.
-
Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab https://www.sciencedirect.com/science/article/abs/pii/S0168365920304831
-
Optimal Approach to the Treatment of Young Adults with Acute Lymphoblastic Leukemia in 2020
https://www.sciencedirect.com/science/article/pii/S0037196320300275 -
Ved ikke om dette fra 27 aug. på Clical trials ( DREAMM 7 ) study , har været vist ?? https://www.clinicaltrials.gov/ct2/show/NCT04246047?term=Darzalex&draw=4&rank=128
-
God morgen.
-
Summary points from expert feedback:
Uptake of Kesimpta will be brisk as it is a known mechanism and modality
Kesimpta’s monthly convenience will drain market share from older injectables
No clear difference on safety/efficacy for anti-CD20 mAbs like Kesimpta and Roche’s Ocrevus -
-
Tak Sukker.
-
Hvis Kesimpta kan dele markedet for nye patienter 50/50 med Ocrevus, så er det bedre end hvad der tidligere er estimeret. Vil være rigtig godt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind